Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

Inclusion Criteria: * KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation. * With evaluable clinical or imaging parameters to monitor disease activity or recurrence. * Patients or their guardians are able to understand the study and provide written informed consent. * Hematologic and hepatic/renal function meet the safety criteria for drug administration. Exclusion Criteria: * Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.